ADC Therapeutics (ADCT) Other Gross PP&E Adjustments: 2019-2023
Historic Other Gross PP&E Adjustments for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to $4.1 billion.
- ADC Therapeutics' Other Gross PP&E Adjustments rose 195.97% to $4.1 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $18.2 billion, marking a year-over-year decrease of 19.79%. This contributed to the annual value of -$15.8 million for FY2022, which is 4.74% up from last year.
- ADC Therapeutics' Other Gross PP&E Adjustments amounted to $4.1 billion in Q3 2023, which was up 37,843.98% from -$11.0 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Other Gross PP&E Adjustments registered a high of $27.0 billion during Q4 2021, and its lowest value of -$4.3 billion during Q3 2022.
- Over the past 3 years, ADC Therapeutics' median Other Gross PP&E Adjustments value was -$7.6 million (recorded in 2021), while the average stood at $3.7 billion.
- As far as peak fluctuations go, ADC Therapeutics' Other Gross PP&E Adjustments plummeted by 66,470.26% in 2021, and later spiked by 195.97% in 2023.
- Over the past 5 years, ADC Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at -$5,256 in 2019, then crashed by 5,901.59% to -$11,343 in 2020, then tumbled by 66,470.26% to $27.0 billion in 2021, then plummeted by 47.89% to $14.1 billion in 2022, then surged by 195.97% to $4.1 billion in 2023.
- Its Other Gross PP&E Adjustments was $4.1 billion in Q3 2023, compared to -$11.0 million in Q2 2023 and -$11.2 million in Q1 2023.